Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Early quantification of HCV core antigen may help to determine the duration of therapy for chronic genotype 2 or 3 HCV infection.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology - 1 Jul 2012

Alsiö A, Jannesson A, Langeland N, Pedersen C, Färkkilä M, Buhl M R, Mørch K, Westin J, Hellstrand K, Norkrans G, Lagging M

Abstract excerpt

The aim of the present study was to evaluate the utility of hepatitis C virus (HCV) core antigen (coreAg) assessment for the identification of candidates for short-term therapy. Plasma samples from HCV genotype 2 or 3-infected patients participating in the NORDynamIC trial (n=382) comparing 12 an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Hepatitis C Antigens

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Polyethylene Glycols

Share to Ribavirin

Share to Viral Core Proteins

Share to Viral Load

Source

Identifiers

PMID: 22113307
DOI: 10.1007/s10096-011-1486-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22113307-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Early quantification of HCV core antigen may help to determine the duration of therapy for chronic genotype 2 or 3 HCV infection.PMID 22113307Read ↗

Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial.Semantic proximity Read ↗

Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection.Semantic proximity Read ↗

Hepatitis C virus core antigen, an earlier and stronger predictor on sustained virological response in patients with genotype 1 HCV infection.Semantic proximity Read ↗

What is the optimal duration of therapy in patients with hepatitis C genotype 2 or 3 infection?: a review.Semantic proximity Read ↗

Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection.Semantic proximity Read ↗

Individualizing treatment duration in hepatitis C virus genotype 2/3-infected patients.Semantic proximity Read ↗

Optimizing the treatment of chronic hepatitis due to hepatitis C virus genotypes 2 and 3: a review.Semantic proximity Read ↗

Tailoring treatment duration to 12 to 16 weeks in hepatitis C genotype 2 or 3 with rapid virologic response: systematic review and meta-analysis of randomized controlled trials.Semantic proximity Read ↗

Early decline of the HCV core antigen can predict SVR in patients with HCV treated by Pegylated interferon plus ribavirin combination therapy.Semantic proximity Read ↗

Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3.Semantic proximity Read ↗

Impact of shorter duration of treatment on virological response rate in genotype 2 or 3 chronic hepatitis C virus infection.Semantic proximity Read ↗

Clinical trial: individualized treatment duration for hepatitis C virus genotype 1 with peginterferon-alpha 2a plus ribavirin.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.